Sakditad Saowapa, Hematology/Oncology Fellow at the University of Iowa, shared a post on X:
“ALINA changes the game for early-stage ALK+ NSCLC: adjuvant alectinib to big DFS gains, fewer brain metastasis, and less toxicity vs chemotherapy.
A new standard emerging.”
More posts featuring Sakditad Saowapa.